Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status

被引：1
|
作者：
Garrison, L. P.
Lalla, D.
Brammer, M. G.
Wang, B.
Babigumira, J.
Perez, E. A.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Mayo Clin, Jacksonville, FL 32224 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.6133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6133
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer
    Garrison, Louis P., Jr.
    Babigumira, Joseph B.
    Masaquel, Anthony
    Wang, Bruce C. M.
    Lalla, Deepa
    Brammer, Melissa
    VALUE IN HEALTH, 2015, 18 (04) : 541 - 546
  • [42] An alternative to HER2 IHC 0/1+/2+status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely superiority of quantitative HER2 pathway RPPA measurements
    Wulfkuhle, Julia
    Wolf, Denise M.
    DeMichele, Angela
    Yau, Christina
    Veer, Laura van T.
    Rugo, Hope S.
    Pusztai, Lajos
    Brown-Swigart, Lamorna
    Hirst, Gillian L.
    Gallagher, Rosa I.
    Delson, Amy L.
    Borowsky, Alexander D.
    Esserman, Laura J.
    Pohlmann, Paula R.
    Petricoin, Emanuel F.
    CANCER RESEARCH, 2024, 84 (03)
  • [43] Influence of HER2 expression status in the distribution of recurrence score from the OncotypeDx assay among women with early-stage estrogen-receptor-positive/HER2-negative breast cancer
    Shah, Anish
    Budhathoki, Pravash
    Gaire, Suman
    Joshi, Utsav
    Yadav, Siddhartha
    CANCER RESEARCH, 2023, 83 (05)
  • [44] Efficacy of Sacituzumab Govitecan (SG) in Patients with metastatic triple negative Breast Cancer (mTNBC) by HER2 Immunohistochemistry (IHC) Status: Results from the Phase 3 ASCENT Study
    Hegewisch-Becker, S.
    Hurvitz, S. A.
    Bardia, A.
    Punie, K.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Carey, L. A.
    Rugo, H. S.
    Yoon, O. K.
    Pan, Y.
    Delaney, R.
    Hofsess, S.
    Hodgkins, P.
    Phan, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 104 - 105
  • [45] Assessment of change in HER2 status and its outcomes after neoadjuvant chemotherapy with trastuzumab and/or pertuzumab in early-stage breast cancer patients
    Godbole, Manasi M.
    Shango, Kathren
    Meranda, Matthew
    Wilson, Carl P.
    Dabak, Vrushali
    CANCER RESEARCH, 2023, 83 (07)
  • [46] Sub classification of early stage hormone positive (HP) Her-2 negative breast cancer (BC) by immunohistochemistry (IHC) into intrinsic subtypes (IS) and their correlation with Oncotype Recurrence Score (RS)
    Mahesh, S.
    Lane, J.
    Ravichandran, P.
    CANCER RESEARCH, 2012, 72
  • [47] Outcome of adjuvant chemotherapy in elderly patients with early-stage, hormone receptor-positive, HER-2-negative breast cancer
    Ma, Sung Jun
    Oladeru, Oluwadamilola T.
    Singh, Anurag K.
    BREAST JOURNAL, 2020, 26 (10): : 2026 - 2030
  • [48] Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study
    Hurvitz, S. A.
    Bardia, A.
    Punie, K.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Carey, L. A.
    Rugo, H. S.
    Yoon, O. K.
    Pan, Y.
    Delaney, R. J.
    Hofsess, S.
    Hodgkins, P.
    Phan, S-C.
    Dieras, V.
    ANNALS OF ONCOLOGY, 2022, 33 : S200 - S201
  • [49] Evaluating the risk of cardiotoxicity associated with concurrent trastuzumab emtansine (TDM1) and radiation therapy in patients with early-stage HER2 positive breast cancer
    Farooq, Faheem
    Cason, Dillon
    Ohri, Nisha
    Kumar, Shicha
    Grann, Allison
    Litvak, Anna
    Ganesan, Shridar
    Haffty, Bruce G.
    Toppmeyer, Deborah
    Omene, Coral
    George, Mridula A.
    CANCER RESEARCH, 2023, 83 (05)
  • [50] Pharmacokinetics of CT-P6 and reference trastuzumab by clinical factors in patients with HER2 positive early-stage breast cancer (EBC)
    Stebbing, Justin
    Yu, SunYoung
    Kim, MinJi
    Park, Sijin
    Kim, SinHye
    Kim, HyunAh
    Kim, NaHyun
    Esteva, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345